<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125762</url>
  </required_header>
  <id_info>
    <org_study_id>2004P000251</org_study_id>
    <nct_id>NCT00125762</nct_id>
  </id_info>
  <brief_title>FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy</brief_title>
  <official_title>Comparison of FibroScan With Histological Evaluations of Liver Fibrosis in Patients With Hepatitis B and C Presenting for Liver Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afdhal, Nezam, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Echosens</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effectiveness of the FibroScan device in differentiating fibrosis
      in patients with hepatitis B and C. The FibroScan measures liver stiffness and will be
      correlated to the liver biopsy to see if it can diagnose the stage of liver disease. Patients
      who are scheduled to have a liver biopsy will also have a fibroscan and the stiffness will be
      correlated with the biopsy stage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVES:

      Co -Primary Aims:

        -  Diagnosis of cirrhosis in patients with chronic viral hepatitis B and C;

        -  Correlation of the FibroScan measurement with Metavir liver fibrosis scores by
           differentiating no/mild fibrosis (F0-F1) from severe fibrosis (F2-F4).

      STUDY DESIGN:

      This is a multi-center study in which the FibroScan measurements will be collected
      prospectively from patients with chronic hepatitis B and C virus presenting for liver biopsy.
      The study duration will be 12 months. The study will initially have 3 investigational sites
      in the United States. Up to 3 more investigational sites may be identified to participate in
      the trial.

      Study Sites:

      Initially the following three sites will participate in the trial:

      Duke University Medical Center, Durham, NC: Keyur Patel, M.D.; Beth Israel Deaconess Medical
      Center and Harvard Medical School, Boston, MA: Nezam H. Afdhal, M.D.; St. Louis University,
      St. Louis, MO: Bruce R. Bacon M.D.

      Study Population:

      Subjects with chronic liver diseases secondary to chronic hepatitis C and hepatitis B,
      undergoing a liver biopsy as the standard of care for their disease, will be eligible for the
      study. Subjects with hepatitis C, co-infected with other infectious viral diseases, such as
      hepatitis B or HIV-1, or both, may also be candidates for study enrollment provided the
      inclusion/exclusion criteria are met.

      The subjects must be scheduled for liver biopsy either prior to treatment (treatment naïve)
      or, if previously treated, they must have been off treatment for at least three (3) months.
      The time between the date of the FibroScan reading and the date of biopsy must not exceed six
      (6) months.

      Sample Size:

      A total of at least 300 evaluable patients (males and females) will be enrolled in this
      study. Enrollment will be considered competitive with no site enrolling more than 50% of the
      study population. Sample size is based on a prevalence of 20% cirrhosis.

      Subject Inclusion Criteria:

        -  Subject is able to give informed consent for this study and agrees to provide a blood
           sample.

        -  Subject must be at least 18 years of age.

        -  Subject has had or will have a liver biopsy for chronic liver disease, secondary to HBV
           or HCV or within 6 months of FibroScan (experimental cohort 1 only).

        -  Subjects who have hepatitis C (HCV) or hepatitis B (HBV) should be treatment naïve or
           off interferon therapy or nucleoside/nucleotide analogs for HBV for a minimum of 3
           months prior to the FibroScan and liver biopsy.

      Subject Exclusion Criteria:

        -  Unable or unwilling to provide informed consent.

        -  Confirmed diagnosis and/or history of malignancy, or other terminal disease.

        -  Uninterpretable biopsy specimen.

        -  Missing critical clinical, biochemical and/or demographic information.

        -  Receiving anti-viral therapy for infection of HCV or HBV within 3 months prior to the
           FibroScan and liver biopsy.

        -  Subject with other chronic liver disease, including Wilson's disease, alpha
           1-antitrypsin deficiency, cholestatic liver disease, or hemochromatosis.

        -  Patient with clinical ascites

        -  Patients with morbid obesity defined as a body mass index (BMI) of greater than or equal
           to 40.

        -  Patients who are pregnant

        -  Patients who have an implantable cardiac device such as defibrillator or pacemaker

      SAMPLE REQUIREMENTS and TESTING:

      A minimum of 8 valid measurements will be obtained for each subject from the right lobe of
      the liver. The tip of the probe transducer will be covered with coupling gel and placed on
      the skin, between the ribs at the level of the right lobe of the liver. The operator,
      assisted by an ultrasonic time motion image, will locate a portion of the liver that is at
      least 4cm thick and free of large vascular structures. The depth of measurement will be
      between 25 mm and 65 mm. During the acquisition subjects will lie on their back with the
      right arm behind the head, in a similar position to that used for liver biopsy. The physician
      will take the measurements with the probe placed in the intercostal space. The median value
      of the estimates will be kept as the elasticity value of the liver for a given patient. The
      entire examination should last approximately 5 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2005</start_date>
  <completion_date type="Actual">October 1, 2008</completion_date>
  <primary_completion_date type="Actual">May 1, 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Investigator unaware of biopsy results</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis Performance of VCTE for Determination of Cirrhosis (Metavir F4) in Patients With Chronic Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV)</measure>
    <time_frame>28 days</time_frame>
    <description>VCTE was used to diagnose cirrhosis F4 in 748 patients undergoing liver biopsy and VCTE within a 28 day time period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Accuracy of VCTE for the Prediction of Metavir Fibrosis Scores by Differentiating no/Mild (F0/F1) From Severe Fibrosis (F2 - F4)</measure>
    <time_frame>Liver Biopsy and VCTE within a time frame of 6 months</time_frame>
    <description>95% CI for Metavir Fibrosis stage 0 -1 consistent with no or mild fibrosis compared to Metavir 2 - 4 which represents significant fibrosis or cirrhosis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">907</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Single Arm undergoing FibroScan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm active comparison of biopsy to vibration controlled elastography</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FibroScan</intervention_name>
    <arm_group_label>Single Arm undergoing FibroScan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able to give informed consent for this study and agrees to provide a blood
             sample.

          -  Subject must be at least 18 years of age.

          -  Subject has had or will have a liver biopsy for chronic liver disease, secondary to
             HBV or HCV or within 6 months of FibroScan (experimental cohort 1 only).

          -  Subjects who have hepatitis C (HCV) or hepatitis B (HBV) should be treatment naïve or
             off interferon therapy or nucleoside/nucleotide analogs for HBV for a minimum of 3
             months prior to the FibroScan and liver biopsy.

        Exclusion Criteria:

          -  Unable or unwilling to provide informed consent.

          -  Confirmed diagnosis and/or history of malignancy, or other terminal disease.

          -  Uninterpretable biopsy specimen.

          -  Missing critical clinical, biochemical and/or demographic information.

          -  Receiving anti-viral therapy for infection of HCV or HBV within 3 months prior to the
             FibroScan and liver biopsy.

          -  Subject with other chronic liver disease, including Wilson's disease, alpha
             1-antitrypsin deficiency, cholestatic liver disease, or hemochromatosis.

          -  Patient with clinical ascites.

          -  Patients with morbid obesity defined as a BMI of greater than or equal to 40.

          -  Patients who are pregnant.

          -  Patients who have an implantable cardiac device such as defibrillator or pacemaker.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nezam H Afdhal, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BIDMC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruce Bacon M.D.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Afdhal NH, Bacon BR, Patel K, Lawitz EJ, Gordon SC, Nelson DR, Challies TL, Nasser I, Garg J, Wei LJ, McHutchison JG. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol. 2015 Apr;13(4):772-9.e1-3. doi: 10.1016/j.cgh.2014.12.014. Epub 2014 Dec 18.</citation>
    <PMID>25528010</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2005</study_first_submitted>
  <study_first_submitted_qc>August 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2005</study_first_posted>
  <results_first_submitted>March 22, 2017</results_first_submitted>
  <results_first_submitted_qc>September 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 27, 2017</results_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Nezam H. Afdhal</investigator_full_name>
    <investigator_title>Professor of Medicine, Part-time</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Arm</title>
          <description>All patients received a liver biopsy and a FibroScan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="907"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="748"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm Undergoing FibroScan</title>
          <description>Single arm active comparison of biopsy to vibration controlled elastography
FibroScan</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="907"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="907"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="907"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="907"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>The analysis is for patients who completed both the liver biopsy and the FibroScan</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="748"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="907"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="586"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="907"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diagnosis Performance of VCTE for Determination of Cirrhosis (Metavir F4) in Patients With Chronic Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV)</title>
        <description>VCTE was used to diagnose cirrhosis F4 in 748 patients undergoing liver biopsy and VCTE within a 28 day time period.</description>
        <time_frame>28 days</time_frame>
        <population>748 patients were eligible for analysis with matching valid liver biopsies and VCTE measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Undergoing FibroScan</title>
            <description>Single arm active comparison of biopsy to vibration controlled elastography
FibroScan</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnosis Performance of VCTE for Determination of Cirrhosis (Metavir F4) in Patients With Chronic Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV)</title>
          <description>VCTE was used to diagnose cirrhosis F4 in 748 patients undergoing liver biopsy and VCTE within a 28 day time period.</description>
          <population>748 patients were eligible for analysis with matching valid liver biopsies and VCTE measurements.</population>
          <units>ROC area</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.87" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Accuracy of VCTE for the Prediction of Metavir Fibrosis Scores by Differentiating no/Mild (F0/F1) From Severe Fibrosis (F2 - F4)</title>
        <description>95% CI for Metavir Fibrosis stage 0 -1 consistent with no or mild fibrosis compared to Metavir 2 - 4 which represents significant fibrosis or cirrhosis</description>
        <time_frame>Liver Biopsy and VCTE within a time frame of 6 months</time_frame>
        <population>456 patients with matching liver biopsy and fibroscan</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm Undergoing FibroScan</title>
            <description>Single arm active comparison of biopsy to vibration controlled elastography
FibroScan</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Accuracy of VCTE for the Prediction of Metavir Fibrosis Scores by Differentiating no/Mild (F0/F1) From Severe Fibrosis (F2 - F4)</title>
          <description>95% CI for Metavir Fibrosis stage 0 -1 consistent with no or mild fibrosis compared to Metavir 2 - 4 which represents significant fibrosis or cirrhosis</description>
          <population>456 patients with matching liver biopsy and fibroscan</population>
          <units>ROC area</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="456"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.83" upper_limit="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During FibroScan</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Arm</title>
          <description>All patients received a liver biopsy and a FibroScan</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="907"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="907"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="907"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nezam Afdhal</name_or_title>
      <organization>BIDMC</organization>
      <phone>6176321118</phone>
      <email>nafdhal@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

